Chemomab Therapeutics reported that it presented two scientific posters supporting the clinical rationale for the company’s primary sclerosing cholangitis, PSC, program at EASL 2023, the Annual Congress of the European Association for the Study of the Liver, which took place June 21-24, 2023 in Vienna, Austria. One of the posters reports on a new proteomic study demonstrating a direct relationship between the pro-inflammatory, pro-fibrotic signaling protein CCL24 and PSC disease-related pathways. It found that patients with high CCL24 levels had upregulated pathways related to PSC and disease severity. CCL24 levels were also significantly correlated with serum proteins associated with inflammation, fibrosis and vascularization. Additionally, in a new in vitro study, CCL24-stimulated hepatic fibroblasts exhibited elevated proteins similar to those seen in patients with severe PSC. Another poster presented at the EASL conference described the clinical design and endpoints for Chemomab’s ongoing double-blind, placebo-controlled, multiple dose Phase 2a trial of CM-101 in PSC patients. Topline results from this trial are anticipated in the latter half of 2024.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CMMB:
